C. Bogani

发表

Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease‐Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1)

Francesco Mannelli, Paola Guglielmelli, Giovanni Barosi, 2007, Stem cells.

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia

P. Guglielmelli, C. Bogani, A. Pancrazzi, 2005, Leukemia.

Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome–Negative Myeloproliferative Neoplasms

D. Palli, F. Annunziato, P. Guglielmelli, 2009, Cancer Epidemiology Biomarkers & Prevention.

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

P. Guglielmelli, C. Bogani, A. Bosi, 2009, Haematologica.

Hypermethylation of CXCR4 Promoter in CD34+ Cells from Patients with Primary Myelofibrosis

P. Guglielmelli, C. Bogani, M. Le Bousse-Kerdilès, 2008, Stem cells.

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

P. Guglielmelli, C. Bogani, A. Pancrazzi, 2008, Haematologica.

B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.

P. Guglielmelli, C. Bogani, A. Pancrazzi, 2007, Haematologica.

Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden

T. Barbui, P. Guglielmelli, C. Bogani, 2007, Leukemia.

A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis

P. Guglielmelli, C. Bogani, A. Pancrazzi, 2006, Leukemia.

Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds.

C. Bogani, A. Pancrazzi, A. Migliaccio, 2005, Blood.

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis

C. Bogani, M. Le Bousse-Kerdilès, A. Vannucchi, 2015, Haematologica.

β3-Adrenoreceptor Blockade Reduces Hypoxic Myeloid Leukemic Cells Survival and Chemoresistance

C. Bogani, A. Vannucchi, P. Chiarugi, 2020, International journal of molecular sciences.

Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines.

L. Formigli, C. Sassoli, C. Bogani, 2009, Cancer research.

Influence of the Jak2 V617F Mutational Load at Diagnosis on Major Clinical Aspects in Patients with Polycythemia Vera.

P. Guglielmelli, C. Bogani, A. Pancrazzi, 2006 .

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera

P. Guglielmelli, C. Bogani, A. Bosi, 2009 .

Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis

P. Guglielmelli, C. Bogani, A. Vannucchi, 2016, British journal of haematology.

Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis

M. Cazzola, S. Bicciato, R. Zini, 2015, International journal of cancer.

Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele.

P. Guglielmelli, C. Bogani, A. Bosi, 2008, Leukemia research.

Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis.

P. Guglielmelli, C. Bogani, A. Pancrazzi, 2005, The American journal of pathology.

MicroRNA expression profile in granulocytes from primary myelofibrosis patients.

R. Zini, S. Ferrari, P. Guglielmelli, 2007, Experimental hematology.

Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera.

G. Martinelli, P. Guglielmelli, C. Bogani, 2011, Blood.

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives

T. Barbui, P. Guglielmelli, C. Bogani, 2009, Journal of cellular and molecular medicine.

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

P. Guglielmelli, C. Bogani, A. Bosi, 2013, PloS one.

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.

M. Cazzola, S. Bortoluzzi, R. Zini, 2014, Blood.

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis

S. Bortoluzzi, R. Zini, S. Ferrari, 2014 .

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms

Niccolò Bartalucci, Alessandro M. Vannucchi, C. Bogani, 2013, Journal of cellular and molecular medicine.

Preclinical Models for Drug Selection in Myeloproliferative Neoplasms

C. Bogani, A. Vannucchi, N. Bartalucci, 2013, Current Hematologic Malignancy Reports.

A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.

P. Guglielmelli, C. Bogani, A. Pancrazzi, 2006, Leukemia.

RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF).

T. Barbui, P. Guglielmelli, C. Bogani, 2009 .

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

S. Ferrari, S. Ferrari, P. Guglielmelli, 2013, Leukemia.

Inconsistencies in the association between the JAK2V617F mutation and PRV‐1 over‐expression among the chronic myeloproliferative diseases

P. Guglielmelli, C. Bogani, A. Pancrazzi, 2006, British journal of haematology.

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

P. Guglielmelli, C. Bogani, A. Vannucchi, 2014 .

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial

P. Guglielmelli, C. Bogani, A. Tefferi, 2015, Blood Cancer Journal.

The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.

P. Guglielmelli, C. Bogani, A. Bosi, 2009 .

Dysregulated Expression of MicroRNA-16 Contributes to Abnormal Erythropoiesis in Patients with Polycythemia Vera

P. Guglielmelli, C. Bogani, S. Salati, 2008 .

Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome–Negative Myeloproliferative Neoplasms

D. Palli, F. Annunziato, P. Guglielmelli, 2009, Cancer Epidemiology Biomarkers & Prevention.